ArticleJournal of mid-life health
Clinicopathological and Immunohistochemical Analysis of Recurrent Endometrial Carcinomas: A Retrospective Study from an Indian Cohort.
Article in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: A significant proportion of endometrial carcinomas (EC) recur, necessitating the identification of prognostic factors to refine treatment strategies. This study aims to identify predictors of recurrence. Materials and Methods: This retrospective analysis examines clinicopathological and immunohistochemical features of recurrent EC in an Indian cohort, which were also categorized by ESMO-ESGO-ESTRO risk stratification. Results: Seventeen cases of recurrent EC (2012-2024) treated in our hospital were analyzed. Surgical resection was performed in 16 patients, with one managed palliatively. All except one recurrence was biopsied. The median age at recurrence was 62 years, with a median recurrence interval of 24 months. Endometrioid carcinoma (64.7%) was the most common histological type. Tumors were nearly evenly distributed between low- versus high grade (41.2% vs. 58.8%) and FIGO Stage I versus II-IV (56.3% vs. 43.8%). Superficial myometrial invasion and diffuse invasion patterns were seen in 62.5% of cases, with inflammatory stromal responses in 43.8%. None exhibited a MELF pattern. High- and high-intermediate-risk tumors comprised 56.3%. Vaginal recurrences ( Conclusion: Risk stratification is a more reliable predictor of recurrence than individual parameters. Vaginal recurrences may not indicate aggressive tumor biology. Loss of PgR expression may contribute to disease progression. Molecular studies and extended follow-up are critical for understanding tumor biology and improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.